RxDoctor Payments Data

Hannah Erdely

Family · Connellsville, PANPI 1124707815

Payments from drug & device makers

$741in general payments, 2019–2025

Across 37 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Novo Nordisk$111
  • AstraZeneca$91
  • Lilly USA, LLC$59
  • Abiomed$50
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$37
  • plus $161 from 7 others

What the payments were for

  • Food & beverage$741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$741 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$21,191
Medicare patients
122
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$94,218
FarxigaDapagliflozin Propanediol68$70,889
JardianceEmpagliflozin55$61,633
EliquisApixaban48$42,900
XareltoRivaroxaban29$38,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,316
TrulicityDulaglutide12$17,971
Tresiba Flextouch U-100Insulin Degludec15$14,826
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$12,719
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$9,769
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$6,810
SynthroidLevothyroxine Sodium58$2,841
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,471
Atorvastatin Calcium239$2,187
Levothyroxine Sodium220$1,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$111$94,21864 claims
AstraZenecaFarxiga$91$70,88968 claims
Boehringer IngelheimJardiance$13$61,63355 claims
PfizerEliquis$36$42,90048 claims
GSKTrelegy Ellipta, Anoro Ellipta$31$36,03549 claims
Lilly USA, LLCTrulicity$59$17,97112 claims
AbbVieSynthroid$234$2,84158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Connellsville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →